Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor

Carcinogenesis

Volumn 31, Issue 6, 2010, Pages 1100-1109

  Smith, Darcey L H ^a   Keshavan, Pavitra ^a   Avissar, Uri ^b   Ahmed, Kashif ^a   Zucker, Stephen D ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; BILIRUBIN; BOVINE SERUM ALBUMIN; CYCLIN D1; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 15; GROWTH FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; KI 67 ANTIGEN; PROTEIN TYROSINE PHOSPHATASE SHP; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; HYPERBILIRUBINEMIA; INTESTINE TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR LOCALIZATION; TUMOR VOLUME; WILD TYPE; ANIMAL; APOPTOSIS; C57BL MOUSE; DRUG EFFECT; DRUG POTENTIATION; GUNN RAT; IMMUNOHISTOCHEMISTRY; METABOLISM; NICK END LABELING; ORAL DRUG ADMINISTRATION; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOMA; ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BETA CATENIN; BILIRUBIN; CELL PROLIFERATION; GENES, APC; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTESTINAL NEOPLASMS; MICE; MICE, INBRED C57BL; RATS; RATS, GUNN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TAUROCHOLIC ACID;

EID: 77953941314     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq050     Document Type: Article

References (57)

1. Greenlee, R.T. et al. (2000) Cancers statistics, 2000. CA Cancer J.Clin., 50, 7-33.
2. Burt, R.W. (2000) Colon cancer screening. Gastroenterology, 119, 837-853.
3. Winawer, S.J. et al. (1993) Prevention of colorectal cancer by colonoscopic polypectomy. N. Engl. J. Med., 329, 1977-1983.
4. Moran, E.M. (2002) Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J. Environ. Pathol. Toxicol. Oncol., 21, 193-201.
5. Giardiello, F.M. et al. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med., 346, 1054-1059.
6. Brooks, P. (1998) Use and benefits of nonsteroidal anti-inflammatory drugs. Am. J. Med., 104, 9S-13S.
7. Kerr, D.J. et al. (2007) Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N. Engl. J. Med., 357, 360-369.
8. Bernstein, H. et al. (2005) Bile acids as carcinogens in human gastrointestinal cancers. Mut. Res., 589, 47-65.
9. Tung, B.Y. et al. (2001) Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann. Intern. Med., 134, 89-95.
10. Earnest, D.L. et al. (1994) Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res., 54, 5071-5074.
11. Jacoby, R.F. et al. (2004) Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology, 127, 838-844.
12. Akare, S. et al. (2006) Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int. J. Cancer, 119, 2958-2969.
13. Wali, R.K. et al. (2002) Ursodeoxycholic acid and F6-D3 inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles for cyclin D1 and E-cadherin. Cancer Epidemiol. Biomarkers Prev., 11, 1653-1662.
14. Khare, S. et al. (2003) Ursodeoxycholic acid inhibits Ras mutations, wildtype ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res., 63, 3517-3523.
15. Wali, R.K. et al. (1995) Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-α, -β II, and -ζ. Cancer Res., 55, 5257-5264.
16. Im, E. et al. (2004) Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J. Nutr., 134, 483-486.
17. Temme, E.H.M. et al. (2001) Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control, 12, 887-894.
18. Zucker, S.D. et al. (2004) Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology, 40, 827-835.
19. Keshavan, P. et al. (2004) Unconjugated bilirubin induces apoptosis in colon cancer cells by triggering mitochondrial depolarization. Int. J. Cancer, 112, 433-445.
20. Rao, P. et al. (2006) Bilirubin exhibits a novel anti-cancer effect on human adenocarcinoma. Biochem. Biophys. Res. Commun., 342, 1279-1283.
21. Jaiswal, M. et al. (2001) Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am. J. Physiol. Gastrointest. Liver Physiol., 281, G626-G634.
22. Wang, W.W. et al. (2004) Bilirubin inhibits iNOS expression and nitric oxide production in response to endotoxin. Hepatology, 40, 424-433.
23. Lester, R. et al. (1963) Intestinal absorption of bile pigments. I. The enterohepatic circulation of bilirubin in the rat. J. Clin. Invest., 42, 736-746.
24. Wasan, H.S. et al. (1997) Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc. Natl Acad. Sci. USA, 94, 3308-3313.
25. Levy, J.R. et al. (1998) Effect of bile acid composition and manipulation of enterohepatic circulation on leptin gene regulation. Metabolism, 47, 285-291.
26. Zucker, S.D. et al. (2001) Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl Acad. Sci. USA, 98, 12671-12676.
27. McDonagh, A.F. et al. (2002) Hepatobiliary excretion of biliverdin isomers and C10-substituted biliverdins in MRP2-deficient (TR)rats. Biochem. Biophys. Res. Commun., 293, 1077-1083.
28. McDonagh, A.F. et al. (1972) The ready isomerization of bilirubin IXα in aqueous solution. Biochem. J., 129, 797-800.
29. Luongo, C. et al. (1994) Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res., 54, 5947-5952.
30. Mahmoud, N.N. et al. (1999) Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. Carcinogenesis, 20, 299-303.
31. Kongkanuntn, R. et al. (1999) Dysregulated expression of b-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice. Oncogene, 18, 7219-7225.
32. Hu, R. et al. (2006) Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis, 27, 2038-2046.
33. Valentin-Vega, Y.A. et al. (2009) Mdm4 loss in the intestine epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation, 77, 442-449.
34. Brink, M.A. et al. (1996) Bilirubin cycles enterohepatically after ileal resection in the rat. Gastroenterology, 110, 1945-1957.
35. Min/+ tumorigenesis. Mol. Cancer Res., 6, 1786-1793.
36. Wolters, H. et al. (2002) Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice. J. Hepatol., 37, 556-563.
37. Wang, H. et al. (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell, 3, 543-553.
38. Yang, F. et al. (2007) Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res., 67, 863-867.
39. Kim, I. et al. (2007) Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis, 28, 940-946.
40. Maran, R.R.M. et al. (2009) Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther., 328, 469-477.
41. Modica, S. et al. (2008) Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res., 68, 9589-9594.
42. Zhang, Y. et al. (2008) Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology, 48, 289-298.
43. Chiang, J.Y. (2009) Bile acids: regulation of synthesis. J. Lipid Res., 50, 1955-1966.
44. Min/+ mice by inhibiting nitric oxide production. Cancer Res., 61, 8357-8360.
45. Min/+ mice. Int. J. Cancer, 121, 506-513.
46. Yamada, C. et al. (2006) Digestion and gastrointestinal absorption of the 1416-kDA rice allergens. Biosci. Biotechnol. Biochem., 70, 1890-1897.
47. Vitek, L. et al. (2003) Enterohepatic cycling of bilirubin as a cause of 'black' pigment gallstones in adult life. Eur. J. Clin. Invest., 33, 799-810.
48. Ho, S.B. et al. (1995) Experimental model of upper intestinal adenocarcinoma induced by N-methyl- N'-nitro- N-nitrosoguanidine in C57BL/6 mice. Cancer Lett., 91, 177-183.
49. Salmon, R.J. et al. (1984) Effect of taurocholic acid feeding on methyl-nitroN-nitroso-guanidine induced gastric tumors. Cancer Lett., 22, 315-320.
50. Corpet, D.E. et al. (2004) Point: from animal models to prevention of colon cancer: systematic review of chemoprevention in Min mice and choice of the model system. Cancer Epidemiol. Biomarkers Prev., 12, 391-400.
51. Shoemaker, A.R. et al. (1997) Studies of neoplasia in the Min mouse. Biochim. Biophys. Acta, 1332, F25-F48.
52. He, N. et al. (2008) Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology, 134, 793-802.
53. Wilding, J. et al. (2002) Cyclin D1 is not an essential target of β-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (Min) mice. Cancer Res., 62, 4562-4565.
54. Vavassori, P. et al. (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol., 183, 6251-6261.
55. Sanchez, N.M. et al. (1998) Ursodeoxycholic acid and cholesterol induce enterohepatic cycling of bilirubin in rodents. Gastroenterology, 115, 722-732.
56. Van der Veere, C.N. et al. (1995) Rapid association of unconjugated bilirubin with amorphous calcium phosphate. J. Lipid Res., 36, 1697-1707.
57. De Gottardi, A. et al. (2004) The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differentially expressed in colon cancer. Dig. Dis. Sci., 49, 982-989.